Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -35.24 Billion KRW | 32.97% |
| 2022 | -52.57 Billion KRW | -8.37% |
| 2021 | -48.51 Billion KRW | 11.91% |
| 2020 | -55.07 Billion KRW | -31.98% |
| 2019 | -41.73 Billion KRW | -108.77% |
| 2018 | -19.99 Billion KRW | -180.9% |
| 2017 | -7.11 Billion KRW | -258.88% |
| 2016 | -1.98 Billion KRW | -279.3% |
| 2015 | 1.1 Billion KRW | 0.0% |
| 2013 | 378.31 Million KRW | 122.57% |
| 2012 | -1.67 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.72 Billion KRW | 8.53% |
| 2024 Q2 | -5.91 Billion KRW | -3.23% |
| 2023 Q4 | -6.26 Billion KRW | 20.12% |
| 2023 FY | -35.24 Billion KRW | 32.97% |
| 2023 Q1 | -12.08 Billion KRW | 14.36% |
| 2023 Q2 | -9.05 Billion KRW | 25.13% |
| 2023 Q3 | -7.84 Billion KRW | 13.36% |
| 2022 FY | -52.57 Billion KRW | -8.37% |
| 2022 Q2 | -12.9 Billion KRW | -10.49% |
| 2022 Q3 | -13.07 Billion KRW | -1.33% |
| 2022 Q1 | -11.67 Billion KRW | 30.06% |
| 2022 Q4 | -14.11 Billion KRW | -7.98% |
| 2021 Q3 | -9.48 Billion KRW | 10.46% |
| 2021 Q4 | -16.69 Billion KRW | -75.96% |
| 2021 FY | -48.51 Billion KRW | 11.91% |
| 2021 Q2 | -10.59 Billion KRW | 9.96% |
| 2021 Q1 | -11.76 Billion KRW | -381.67% |
| 2020 FY | -55.07 Billion KRW | -31.98% |
| 2020 Q1 | -11.42 Billion KRW | -14.1% |
| 2020 Q2 | -26.79 Billion KRW | -134.46% |
| 2020 Q3 | -14.41 Billion KRW | 46.22% |
| 2020 Q4 | -2.44 Billion KRW | 83.04% |
| 2019 Q2 | -10.06 Billion KRW | -13.22% |
| 2019 FY | -41.73 Billion KRW | -108.77% |
| 2019 Q1 | -8.88 Billion KRW | -13.12% |
| 2019 Q4 | -10.01 Billion KRW | 21.57% |
| 2019 Q3 | -12.77 Billion KRW | -26.95% |
| 2018 FY | -19.99 Billion KRW | -180.9% |
| 2018 Q3 | -5.87 Billion KRW | -56.08% |
| 2018 Q4 | -7.85 Billion KRW | -33.66% |
| 2018 Q2 | -3.76 Billion KRW | -51.09% |
| 2018 Q1 | -2.49 Billion KRW | -33.94% |
| 2017 Q3 | -1.77 Billion KRW | 0.35% |
| 2017 FY | -7.11 Billion KRW | -258.88% |
| 2017 Q2 | -1.78 Billion KRW | -5.27% |
| 2017 Q1 | -1.69 Billion KRW | 0.0% |
| 2017 Q4 | -1.86 Billion KRW | -4.68% |
| 2016 FY | -1.98 Billion KRW | -279.3% |
| 2015 FY | 1.1 Billion KRW | 0.0% |
| 2014 Q1 | -864.9 Million KRW | -191.16% |
| 2014 Q3 | -507.81 Million KRW | -181.05% |
| 2014 Q2 | -180.68 Million KRW | 79.11% |
| 2013 FY | 378.31 Million KRW | 122.57% |
| 2013 Q3 | 13.51 Million KRW | 109.24% |
| 2013 Q2 | -146.2 Million KRW | 66.6% |
| 2013 Q1 | -437.79 Million KRW | 45.13% |
| 2013 Q4 | 948.8 Million KRW | 6922.49% |
| 2012 FY | -1.67 Billion KRW | 0.0% |
| 2012 Q4 | -797.81 Million KRW | -324.33% |
| 2012 Q3 | 355.64 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 71.809% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -972.934% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 3481.627% |
| Bioneer Corporation | 791.75 Million KRW | 4551.573% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -594.65% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | -40.249% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | -14.015% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -273.95% |
| Medy-Tox Inc. | 17.32 Billion KRW | 303.468% |
| Peptron, Inc. | -15.6 Billion KRW | -125.89% |
| Amicogen, Inc. | 2.05 Billion KRW | 1814.156% |
| Genexine, Inc. | -41.24 Billion KRW | 14.538% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -305.108% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 56.391% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -261.98% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 134.96% |
| SillaJen, Inc. | -21.34 Billion KRW | -65.116% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 1438.28% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -93.812% |
| Genomictree Inc. | -17.3 Billion KRW | -103.69% |
| MedPacto, Inc. | -28.75 Billion KRW | -22.584% |
| D&D Pharmatech | -13.48 Billion KRW | -161.344% |
| EASY BIO,Inc. | 20.63 Billion KRW | 270.836% |
| GI Innovation, Inc. | -55.6 Billion KRW | 36.613% |